A clinical perspective on ectopic Cushing's syndrome
Trends Endocrinol Metab. 2023 Dec 23:S1043-2760(23)00248-5. doi: 10.1016/j.tem.2023.12.003. Online ahead of print.ABSTRACTCushing's syndrome (CS) refers to the clinical features of prolonged pathological glucocorticoid excess. About 10-20% of individuals with CS have ectopic CS (ECS), that is, an adrenocorticotropin (ACTH)-producing tumour outside the pituitary gland. ACTH-secreting neuroendocrine neoplasia (NENs) can arise from many organs, although bronchial NEN, small cell lung cancer (SCLC), pancreatic NEN, thymic NEN, medullary thyroid cancer (MTC), and pheochromocytoma are the most common. Patients with ECS frequently present with severe hypercortisolism. The risk of life-threatening complications is high in severe cases, unless the hypercortisolism is effectively treated. A good outcome in ECS requires a methodical approach, incorporating prompt diagnosis, tumour localization, control of cortisol excess, and resection of the primary tumour when possible.PMID:38143211 | DOI:10.1016/j.tem.2023.12.003
Source: Trends in Endocrinology and Metabolism: TEM - Category: Endocrinology Authors: Oskar Ragnarsson C Christofer Juhlin David J Torpy Henrik Falhammar Source Type: research
More News: Brain | Bronchial Tumour | Cancer | Cancer & Oncology | Cushing's Syndrome | Endocrinology | Lung Cancer | Neurology | Pancreas | Pancreatic Cancer | Pheochromocytoma | Small Cell Lung Cancer | Thyroid | Thyroid Cancer